Antimicrobial resistance companies develop diagnostics, therapeutics and technologies to address infections that no longer respond effectively to existing medicines. Their work supports faster pathogen identification, improved treatment decisions and the development of new approaches to infection control.
This category includes companies working on:
Browse 53 UK antimicrobial resistance companies below.
Rapid point-of-care antibiotic susceptibility testing for antimicrobial resistance
Microplate Dx is a diagnostics biotechnology company developing a rapid antibiotic susceptibility testing platform for use at the point of care. Its biosensor technology uses hydrogel-modified electrodes loaded with antibiotics to determine the most effective treatment for a patient's bacterial infection in under one…
Natural antimicrobial solutions to reduce livestock antibiotic use
Feed, Food & Future is a life sciences company developing and testing natural antibacterial and antiviral ingredients for the animal feed and livestock industries. Operating from a BSL2 laboratory at Cardiff Medicentre, the company researches plant-based and natural molecules as alternatives to conventional…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder…
Preclinical vaccines targeting antimicrobial-resistant bacterial infections
VacTimmune is a biotechnology company developing preventative vaccines against bacterial pathogens associated with antimicrobial resistance. Its preclinical pipeline includes candidates targeting Pseudomonas aeruginosa, Klebsiella pneumoniae and other clinically important bacteria, with an emphasis on infections…
Rapid genomic diagnostic device for sepsis and bacterial infections
GenomeKey is a biotechnology company developing an in vitro diagnostic device that uses whole genome sequencing and machine learning to identify bacteria and their antimicrobial resistance profiles directly from patient blood within hours. The device targets sepsis, where current culture-based diagnostics take 24 to…
Anti-virulence drug discovery from natural bioactive compounds
Neem Biotech is a Wales-based drug discovery company developing novel non-traditional antimicrobial treatments derived from naturally inspired compounds. The company specialises in quorum sensing inhibitors and anti-biofilm agents, with programmes targeting wound infection and cystic fibrosis. Its discovery approach…
Rapid point-of-care molecular diagnostics for infectious disease
Llusern Scientific is a diagnostics company developing portable, rapid molecular diagnostic systems for use at the point of care. Using isothermal amplification technology, the company's platform identifies bacterial pathogens directly from patient samples without laboratory infrastructure, delivering results within…
Contract research for animal health, aquaculture and biopharmaceutical biosafety
Moredun Scientific is a contract research organisation providing efficacy and safety testing services for veterinary and aquaculture products, and biosafety testing of biopharmaceuticals. The company conducts studies across major livestock species and fish using validated infectious disease models for bacteria,…
Clinical-stage anti-infectives targeting antimicrobial resistance and infectious disease
NovaBiotics is a clinical-stage biotechnology company developing first-in-class anti-infective therapies for difficult-to-treat infectious diseases, with a focus on antimicrobial resistance. Its pipeline is built on two proprietary platforms: an anti-infective peptide platform yielding antifungal and antibacterial…
Computational cell models for novel drug target discovery
Oppilotech is a UK biotechnology company that uses systems biology and machine learning to build high-resolution computational models of cells and bacteria. Its proprietary platform simulates biochemical pathways to identify viable drug targets and generate first-in-class discovery programmes. The company's primary…
Enzyme-free multiplex RNA diagnostics for rapid clinical decisions
Cambridge Nucleomics is a biotechnology company developing a proprietary nanopore-based platform for rapid, high-multiplexed detection of nucleic acid biomarkers. Its enzyme-free soluble nanoarray technology enables simultaneous quantification of up to 200 RNA and DNA targets from low-input samples within one hour.…
Nitric oxide therapeutics developer for infectious and respiratory disease
30 Technology is a clinical-stage biopharmaceutical company developing nitric oxide-generating therapies for the treatment of antimicrobial-resistant infections and chronic respiratory diseases. The company’s proprietary platform enables controlled, sustained delivery of nitric oxide across inhaled, topical and powder…
Rapid microfluidic antimicrobial susceptibility testing for clinical laboratories
iFAST Diagnostics is a biotechnology company developing microfluidic instruments for rapid antimicrobial susceptibility testing of bacterial infections. Its platform uses electrical measurements of individual bacteria following antibiotic exposure to determine susceptibility and minimum inhibitory concentrations in…